In this issue, the article by Murthy and Rajshekar, [1] monthly intervals rather than three monthly intervals, as documents the cost of treating patients with seizures due the benefit of doing imaging at shorter intervals is minimal. to a solitary cysticercus granuloma (SCG). The cost of The only likely benefit of more frequent imaging is that it managing a patient was calculated from the time the patient could avoid prolongation of AED usage in those in whom registered at their clinic till resolution of the granuloma there is early resolution of the granuloma. However, a was documented on the computerized tomography (CT) longer interval between imaging would increase the scan. They arrived at a figure of INR 7273.7 per patient at likelihood of a resolution and thus lower the cost of 1997 rates. They then calculated the economic burden of management not only in individual patients but also in this disease to the country at large by extrapolating the the group as a whole, by reducing the number of CT prevalence figures obtained in their community-based study scans that are required to document the resolution of the of prevalence of SCG in a rural community in Andhra granuloma. Finally, the costs as calculated by the authors Pradesh, to the country's population. The prevalence of may not be universally applicable to the diverse types of SCG was shown to be 0.1 per 1000 in their study and health delivery systems that prevail in the country. thus the number of patients with SCG in the country as a
Why are studies such as these important? Policy makers whole was calculated as 1,10,700 patients. This number can use figures from such studies to determine the priority was multiplied by the total cost of treatment per patient to that is to be accorded to a particular disease in terms of arrive at the final figure of INR 1.184 billion (this figure is formulating public health control and prevention adjusted for inflation as the cost calculated initially was at measures. Every disease imposes economic costs and 1997 rates). This figure in US$ is 26.05 million and not as social and mental costs (that cannot be estimated in dollar reported by the authors (US$ 2.605 million).
terms) on the affected individual. However, in preventable A comprehensive estimate of the economic burden of diseases such as NCC there exists an opportunity to avoid epilepsy in India carried out in six public and private these costs to the society. Public health authorities have medical centers in the country estimated that the cost of to work out the costs of prevention keeping in mind the managing patients with epilepsy was INR 68.75 billion cost of the disease to the community. at 1998 rates. [2] However, the cost of treating seizures due Besides, the economic cost of illness, the DALY to a particular disease entity such as SCG has not been (disability adjusted life years) count of a disease also plays studied. The authors are to be commended for performing a crucial role in determining its importance in the public a meticulous study. However, there are some issues that come to mind. The cost was calculated from the time the patient visited the authors' clinic. It is not clear whether the cost of treating seizures (both direct medical costs and wages lost), which occurred before the patient visited their clinic, was included in their final calculation. This is a significant burden as the mean number of seizures before the visit was nearly four and the mean duration of illness was nearly 12 months. During this period even if the patients did not receive anti-epileptic drugs (AEDs), there would have been significant loss of wages. Another issue that is debatable is the frequency of repeat CT imaging after the initial repeat CT done 6 months after the diagnosis. CT scans could probably be repeated at six health agenda. In the context of prevention and control, control of SCG entails control of NCC. Therefore, ideally one would like to know the cost of treating patients with all the manifestations of NCC. Admittedly, this is a difficult task as there are no prevalence studies from our country for the various presentations of NCC. Recently, we estimated the contribution of NCC to the causation of active epilepsy (AE) in a community based study using CT imaging. [3] Our study revealed that the prevalence rate of AE due to NCC was one per 1000 population and thus, at least one million patients in the country suffer from AE due to NCC. It is easy to comprehend that the cost of treating this large number of patients with AE (which requires treatment with AEDs for a prolonged Rajshekhar: Cost of treating patients with solitary cysticercus granulomas period) will be much higher than the cost of treating patients with SCG alone. The huge economic costs could then be used to convince policy makers of the need to institute control measures even though capital and recurring costs might be high in the short term. This article should inspire others to study the cost of managing common neurological and neurosurgical diseases of public health importance and thereby draw the attention of policy makers to the economic importance of implementing disease-appropriate control measures.
